ClinicalTrials.gg
CompletedNCT04868981Updated Jun 7, 2022

Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets

A Phase 1 interventional study of GST-HG141 tablets and Matching Placebos for GST-HG141 tablets in Hepatitis B, sponsored by Fujian Cosunter Pharmaceutical Co. Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-07.

Sponsored by Fujian Cosunter Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 192 studies in Hepatitis B with a site in China — 39 open to participants now, 49 under way, 1 of them phase 3. Hepatitis B · China.

Enrollment
121st of 136
30 · median 123
Started
2021
with 9 others
Phase 1
19 of 192
7 open now
Registered
146th of 192
by date

Among the 192 studies in Hepatitis B with a site in China, this one is the 121st largest by enrollment of the 136 interventional ones that give a count, is one of 10 that started in 2021, is one of 19 in phase 1, and was the 146th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

39 of the 192 studies in Hepatitis B with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 192 studies in Hepatitis B with a site in China, or all of them as a file.
02

Study summary

To Evaluate the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets in Multiple-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Multiple-administration Study in Patients With Chronic Hepatitis B (CHB)

Read the detailed description

This study includes 3 cohorts of 25 mg BID, 50 mg BID and 100 mg BID. 30 patients with chronic hepatitis B will be enrolled in this study and each cohort will enroll 10 patients (GST-HG141 tablets : PBO=8:2). All enrolled patients will be given research drugs twice a day for 28 days (D28 was administered only once in the morning). And each cohort requires at least 4 subjects with elevated ALT. Tolerability, pharmacodynamics and pharmacokinetics will be evaluated according to the protocol.

03

Conditions studied

  • Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the before the study and fully understand the content and process of the study as well as the possible adverse drug reactions;
  2. Be able to complete the study in accordance with protocol requirements;
  3. Subjects (including partners) are willing to take effective measures from completion of screening to 6 months after the last Administration;
  4. Ages ranged from 18 to 70 years old (including 18 and 70 years old);
  5. Male subjects weighing no less than 45 kg, and female subjects weighing no less than 40 kg. [ (BMI) = body weight (kg) / height 2 (m\^2)], body mass index is in the range of 18 \~ 32 kg / m\^2 (including critical value);
  6. Patients with -positive for at least 6 months (based on outpatient/inpatient medical records or laboratory report; or with IgM HBcAb-negative and HBsAg-positive when screening;
  7. Patients without interferon/nucleoside analogue treatment when screening, or interferon treatment was stopped more than 1 year ago, and nucleoside analogue treatment was stopped more than 6 months ago.
  8. For HBeAg-positive patients, HBV DNA ≥ 2×10\^5 IU/mL; For HBeAg-negative patients, HBV DNA ≥ 2×10\^4 IU/mL;
  9. Patients with Serum less than 5× when screening.

Exclusion criteria

Exclusion Criteria:

  1. Patients with suspected allergy to any component of the study drug or allergic constitution (multiple drug and food allergy);
  2. Patients who had major trauma or Large surgical operation within 3 months before screening or are planning to take surgical treatment during the study ;
  3. Patients who had blood donation or massive blood loss (≥400 mL), or had a blood transfusion within 3 months before screening; or had blood donation or massive blood loss (≥200 mL) within 1 months before screening;
  4. Patients with smoking more than 5 cigarettes per day within 3 months before the study or heavy drinking within 4 weeks before screening (drinking more than 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
  5. Patients who had used , immunomodulators (thymosin) and cytotoxic drugs within 6 months before dosing, or had received within 1 month before screening;
  6. Patients who used immunosuppressants, immunomodulators (thymosin) and cytotoxic drugs within 6 months before dosing, or who had received live attenuated vaccine within 1 month before screening;
  7. Patients with acute or chronic liver disease caused by non infection (fatty liver disease is ruled out or recruited by researcher);
  8. Patients with history of liver cirrhosis or progressive liver fibrosis (e.g., liver histopathology reported liver cirrhosis or endoscopy indicated esophageal and gastric varices);
  9. Patients with confirmed or suspected decompensated hepatitis B cirrhosis including but not limited to: hepatic encephalopathy, hepatorenal syndrome, esophageal and gastric variceal bleeding, splenomegaly, ascites, primary liver cancer, etc. ;
  10. Patients with history of other or complicating with other malignant tumors;
  11. Patients complicating with severe circulatory, digestive, respiratory, urinary, blood, metabolism, immune, nervous and other systemic;
  12. Patients with acute infection within 2 weeks before screening;
  13. Patients who had participated in clinical trials of drugs or medical devices within 1 month before screening;
  14. Patients who could not ban smoking, drinking, caffeinated food or drinks within 2 days before administration and during the study , and patients who have special dietary requirements and can not follow the unified diet;
  15. Laboratory examination: count\<90×10\^9/L; leukocyte count\<3.0×10\^9/L; neutrophil absolute value\<1.3×10\^9/L; serum total >2×; albumin\<30 g/L; rate≤60ml/min (calculated by formula); international standardization ratio value of (INR) >1.5;
  16. Patients with Alpha fetoprotein (AFP) more than 50 UG / L or imaging findings of malignant liver lesions;
  17. Patients with HCAb-positive , AIDS Ag/Ab-positive, or positive syphilis spirochemical Ab simultaneously RPR test-positive;
  18. For patients with normal or less than 2×ULN, LSM≥12.4 kPa; or for patients with ALT≥2×ULN, LSM≥17.0 kPa;
  19. Patients with positive urine drug screening (morphine, marijuana) or alcohol breath test;
  20. Patients with positive urine drug screening (morphine, marijuana) or alcohol breath test;
  21. Patients with other factors that are not suitable to participate in this study in researcher's thought.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    GST-HG141

    GST-HG141 tablets at varying dosages by mouth for 28 days

    Drug: GST-HG141 tablets

  • Placebo comparator
    Matching Placebo for GST-HG141

    Placebos for GST-HG141 tablets at varying dosages by mouth for 28 days

    Drug: Matching Placebos for GST-HG141 tablets

Interventions

  • Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses

  • DrugMatching Placebos for GST-HG141 tablets

    Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses

06

What researchers measure

Primary outcomes

  1. Number of patients with chronic HBV infection with treatment-related adverse events and laboratory abnormalities.

    Symptoms and physical examination, clinical laboratory examination, vital signs,12 lead ECG and adrenal ultrasounds were collected and assessed by CTCAE v5.0.

    Time frame: Up to 33 days

  2. Cmax of GST-HG141

    Plasma samples were collected at different points for pharmacokinetic analysis

    Time frame: Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.

  3. AUC of GST-HG141

    Plasma samples were collected at different points for pharmacokinetic analysis

    Time frame: Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.

  4. t1/2 of GST-HG141

    Plasma samples were collected at different points for pharmacokinetic analysis

    Time frame: Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.

  5. Cl/F of GST-HG141

    Plasma samples were collected at different points for pharmacokinetic analysis

    Time frame: Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.

Secondary outcomes

  1. The value of serum HBV DNA decreased from baseline

    Plasma samples were collected at different points for pharmacodynamics analysis

    Time frame: Plasma samples were collected before administation on the morning of day 1 and day 15 and at any time on day 29 and day 33

  2. The value of serum HBV pgRNA decreased from baseline

    Plasma samples were collected at different points for pharmacodynamics analysis

    Time frame: Plasma samples were collected before administation on the morning of day 1 and day 15 and at any time on day 29 and day 33

  3. The value of serum HBsAg decreased from baseline

    Plasma samples were collected at different points for pharmacodynamics analysis

    Time frame: Plasma samples were collected before administation on the morning of day 1 and day 15 and at any time on day 29 and day 33

  4. The value of serum HBeAg decreased from baseline

    Plasma samples were collected at different points for pharmacodynamics analysis

    Time frame: Plasma samples were collected before administation on the morning of day 1 and day 15 and at any time on day 29 and day 33

07

Study locations

1 site
  • The first hospital of Jilin University
    Changchun, Jilin 130000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Feb 2022, 8 months.

Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 8 months is below that.

Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2021
First posted
May 3, 2021
StartActual
May 31, 2021
Primary completionActual
Feb 23, 2022
CompletionActual
Mar 14, 2022
Last update
Jun 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04868981
Lead sponsor
Fujian Cosunter Pharmaceutical Co. Ltd
Responsible party
Sponsor
First posted
May 3, 2021
Start date
May 31, 2021
Primary completion
Feb 23, 2022
Completion
Mar 14, 2022
Last update
Jun 7, 2022

Study contacts

Junqi Niu, PhD
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neracorvir

Start the discussion